BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 19, 2026
Home » Topics » Deals and M&A » Acquisition

Acquisition
Acquisition RSS Feed RSS

Acquisition target

Blackrock Neurotech snaps up Mindx to drive brain-computer interface implants

April 25, 2022
By Meg Bryant
Blackrock Neurotech LLC has acquired spatial computing software startup Mindx Corp. to advance full-stack brain-computer interface (BCI) products. As part of the transaction, Mindx’s augmented reality (AR) and artificial intelligence (AI) technology will be integrated with Blackrock’s BCI hardware.
Read More

Backin’ the RSV: Pfizer expands its programs viral programs with Reviral acquisition

April 7, 2022
By Lee Landenberger
Pfizer Inc., with pockets bulging from COVID-19 vaccine money, is taking another step in respiratory syncytial virus (RSV) development with its acquisition of Reviral Ltd.
Read More
M&A cityscape

Avanos buying osteoarthritis injection company Orthogen Rx for $160M

Dec. 14, 2021
By Catherine Longworth
Avanos Medical Inc. is acquiring Orthogen Rx Inc. for $160 million in a bid to strengthen its chronic pain portfolio. China led the contribution to India’s med-tech imports with  ₹91.12 billion (US$1.2 billion) worth of goods in the 2021 fiscal year (April 2020 to March 2021), according to an analysis of data from India’s Department of Commerce by the Association of Indian Medical Device Industry (AIMED). 
Read More
Illustration of big fish eating three smaller fish

Pfizer buys Arena for $6.7B, adding Xeljanz successor to pipeline

Dec. 13, 2021
By Richard Staines
Pfizer Inc. is to buy Arena Pharmaceuticals Inc. for $6.7 billion, adding a potential follow-up to inflammatory diseases pill Xeljanz (tofacitinib) to its pipeline plus several other potential medicines targeting gastroenterology, dermatology and cardiology.
Read More
Sanofi campus in Gentilly, France

Sanofi adds to transplant business with $1.9B acquisition of Kadmon

Sep. 8, 2021
By Richard Staines
Sanofi SA has added to its general medicines portfolio with a $1.9 billion acquisition of Kadmon Holding Inc. and its recently-approved graft-vs.-host disease drug Rezurock (belumosudil).
Read More
Hand holding "Acquisition" piece over puzzle

Pfizer bets on CD47 blockade in cancer with $2.3B Trillium bid

Aug. 23, 2021
By Cormac Sheridan
Pfizer Inc. has turned up the temperature in the already hot CD47 inhibitor space by offering $18.50 per share or $2.26 billion cash to acquire Trillium Therapeutics Inc., a biotech with two clinical-stage CD47 inhibitors.
Read More
Handshake, businessmen holding dollar sign, lightbulb

IPO no-go, Bayer swayer in $2B Vividion deal

Aug. 5, 2021
By Randy Osborne
A little over a month after Versant Ventures-back Vividion Therapeutics Inc. filed to raise $100 million in an IPO, Bayer AG is paying $1.5 billion up front, with the promise of $500 million more in milestone payments, to take over the firm and its small-molecule precision oncology and immunology platform.
Read More
Illustration of big fish eating three smaller fish

Sanofi doubles down on mRNA with $3.2B Translate Bio buy

Aug. 3, 2021
By Richard Staines

Just weeks after announcing plans to invest billions in an mRNA therapeutics research center, Sanofi SA has acquired Translate Bio Inc. for $3.2 billion, building on a development partnership focused around the technology.


Read More
Illustration of big fish eating three smaller fish

Neogenomics moves up bid to buy liquid biopsy specialist Inivata for $390M

May 6, 2021
By Nuala Moran
LONDON – Neogenomics Inc. reported it plans to acquire Inivata Ltd., taking up a $390 million fixed price option to purchase the liquid biopsy specialist eight months early. The option was agreed to in May 2020, when Neogenomics made a $25 million minority equity investment in Inivata and was granted the right to acquire the rest of the company by the end of 2021.
Read More
M&A cityscape

Microsoft makes major commitment to health care with $19.7B Nuance buy

April 12, 2021
By Annette Boyle
Microsoft Corp. will purchase Nuance Communications Inc. for $19.7 billion in cash in a move that demonstrates a massive commitment to building out the Microsoft Cloud for Healthcare reported in late 2020. The acquisition, which is expected to close by the end of 2021, doubles the Redmond, Wash.-based company’s total addressable market in the health care provider space, bringing it to nearly $500 billion. The size of the transaction is notable even for a company with the active acquisition history of Microsoft.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 18, 2026.
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Ebola virus particle

    Authorities work to quickly sequence Ebola species in latest outbreak

    BioWorld
    If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
  • Two silhouettes with tangle, gear, spiral

    NTX-819, a novel mGlu7 NAM for psychiatric disorders

    BioWorld Science
    Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing